Hypofractionated Intensity-modulated Radiotherapy with Simultaneous Integrated Boost after Radical Prostatectomy: Preliminary Results of a Phase II Trial

被引：1

作者：

Massaccesi, Mariangela ^{[1
]}

Cilla, Savino ^{[2
]}

Deodato, Francesco ^{[1
]}

Digesu, Cinzia ^{[1
]}

Macchia, Gabriella ^{[1
]}

Caravatta, Luciana ^{[1
]}

Ippolito, Edy ^{[1
]}

Picardi, Vincenzo ^{[1
]}

Ferro, Marica ^{[1
]}

Mignogna, Samantha ^{[3
]}

Mattiucci, Gian Carlo ^{[4
]}

Valentini, Vincenzo ^{[4
]}

Piermattei, Angelo ^{[2
]}

Morganti, Alessio Giuseppe ^{[1
,3
,4
]}

机构：

[1] Giovanni Paolo II Fdn Ric & Cura, Dept Oncol, Radiotherapy Unit, Campobasso, Italy

[2] Giovanni Paolo II Fdn Ric & Cura, Dept Oncol, Med Phys Unit, Campobasso, Italy

[3] Giovanni Paolo II Fdn Ric & Cura, Dept Oncol, Palliat Therapies Unit, Campobasso, Italy

[4] S Cuore Catholic Univ, A Gemelli Univ Hosp, Dept Radiotherapy, Rome, Italy

来源：

ANTICANCER RESEARCH | 2013年 / 33卷 / 06期

关键词：

Post-operative radiotherapy; prostate cancer; hypofractionation; SIB-IMRT; phase II trial; POSTOPERATIVE RADIOTHERAPY; ADJUVANT RADIOTHERAPY; RADIATION-THERAPY; CANCER; RISK; DEFINITION; GUIDELINES;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To report the acute toxicity of a hypofractionated regimen of intensity-modulated radiotherapy with simultaneous integrated boost (SIB-IMRT) to the pelvic nodes and the prostatic bed after radical prostatectomy. Patients and Methods: Patients with prostate adenocarcinoma at high risk of relapse after radical prostatectomy or with biochemical relapse were deemed eligible for study. SIB-IMRT was prescribed to the whole pelvis (45-Gy delivered in 1.8-Gy fractions) and the prostatic bed [62.5 Gy, 2.5-Gy fractions, Equivalent Dose in 2-Gy fraction (EQD2)=68.75 Gy, alpha/beta=3]. Acute toxicity was recorded and graded according to Radiation Therapy Oncology Group (RTOG) criteria. Results: Forty-nine patients were enrolled. No cases of grade acute >= 3 toxicity were recorded. Grade 2 acute genitourinary and gastrointestinal toxicity was observed in 9.6% and 29.7% of patients, respectively. Conclusion: After radical prostatectomy, hypofractionated high-dose SIB-IMRT enables for reduction of the overall treatment time, with an acute toxicity profile which compares favourably with that of conventionally fractionated high-dose three-dimensional conformal radiotherapy (3D-CRT).

引用

页码：2785 / 2789

页数：5

共 24 条

[1]

Alongi F, 2012, TUMORI, V97, P1

[2] IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy [J].

Alongi, Filippo ;

Fiorino, Claudio ;

Cozzarini, Cesare ;

Broggi, Sara ;

Perna, Lucia ;

Cattaneo, Giovanni Mauro ;

Calandrino, Riccardo ;

Di Muzio, Nadia .

RADIOTHERAPY AND ONCOLOGY, 2009, 93 (02) :207-212

[3]

[Anonymous], 2010, Journal of the ICRU, V10

[4] The influence of lymph node counts on the detection of pelvic lymph node metastasis in prostate cancer [J].

Barth, PJ ;

Gerharz, EW ;

Ramaswamy, A ;

Riedmiller, H .

PATHOLOGY RESEARCH AND PRACTICE, 1999, 195 (09) :633-636

[5] Conformal Postoperative Radiotherapy in Patients With Positive Resection Margins and/or pT3-4 Prostate Adenocarcinoma [J].

Bellavita, Rita ;

Massetti, Michela ;

Abraha, Iosief ;

Lupattelli, Marco ;

Mearini, Luigi ;

Falcinelli, Lorenzo ;

Farneti, Alessia ;

Palumbo, Isabella ;

Porena, Massimo ;

Aristei, Cynthia .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03) :E299-E304

[6] Postoperative radiotherapy after radical prostatectomy:: a randomised controlled trial (EORTC trial 22911) [J].

Bolla, M ;

van Poppel, H ;

Collette, L ;

van Cangh, P ;

Vekemans, K ;

Da Pozzo, L ;

de Reijke, TM ;

Verbaeys, A ;

Bosset, JF ;

van Velthoven, R ;

Maréchal, JM ;

Scalliet, P ;

Haustermans, K ;

Piérart, M .

LANCET, 2005, 366 (9485) :572-578

[7]

Brenner DJ, 2002, INT J RADIAT ONCOL, V52, P6

[8] A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer [J].

Cagiannos, I ;

Karakiewicz, P ;

Eastham, JA ;

Ohori, M ;

Rabbani, F ;

Gerigk, C ;

Reuter, V ;

Graefen, M ;

Hammerer, PG ;

Erbersdobler, A ;

Huland, H ;

Kupelian, P ;

Klein, E ;

Quinn, DI ;

Henshall, SM ;

Grygiel, JJ ;

Sutherland, RL ;

Stricker, PD ;

Morash, CG ;

Scardino, PT ;

Kattan, MW .

JOURNAL OF UROLOGY, 2003, 170 (05) :1798-1803

[9] Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes [J].

Cookson, Michael S. ;

Aus, Gunnar ;

Burnett, Arthur L. ;

Canby-Hagino, Edith D. ;

D'Amico, Anthony V. ;

Dmochowski, Roger R. ;

Eton, David T. ;

Forman, Jeffrey D. ;

Goldenberg, S. Larry ;

Hernandez, Javier ;

Higano, Celestia S. ;

Kraus, Stephen R. ;

Moul, Judd W. ;

Tangen, Catherine ;

Thrasher, J. Brantley ;

Thompson, Ian .

JOURNAL OF UROLOGY, 2007, 177 (02) :540-545

[10] TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].

COX, JD ;

STETZ, J ;

PAJAK, TF .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346

← 1 2 3 →